Clinical trial
A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial to Demonstrate Clinical Efficacy on Cognitive, Neuropsychiatric and Functional Outcomes of Ambroxol in New and Early Patients With Prodromal and Mild Dementia With Lewybodies (ANeED) - Joint Effort 21: eHealth and a PPI-program in Dementia With Lewybodies (DLB)
NCT05773443 is registered in ClinicalTrials.gov with University of Bergen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial to Demonstrate Clinical Efficacy on Cognitive, Neuropsychiatric and Functional Outcomes of Ambroxol in New and Early Patients With Prodromal and Mild Dementia With Lewybodies (ANeED) - Joint Effort 21: eHealth and a PPI-program in Dementia With Lewybodies (DLB)
- Lead sponsor
- University of Bergen
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- March 31, 2023
- Completion date
- December 31, 2026
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
dementia, lewy body